Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.
BACKGROUND
Cytoplasmic p90 autoantigen was recently cloned from a cDNA expression library using serum antibody from a cancer patient. The humoral immune response to p90 in prostate cancer and benign prostatic hyperplasia (BPH) was examined.


METHODS
An antigenic fragment of recombinant p90 protein and several other tumor-associated antigens (TAAs) were used in ELISA and Western blotting to detect antibodies in sera from patients with prostate cancer, BPH, and other controls.


RESULTS
Autoantibodies to p90 were detected in 30.8% of 133 prostate cancer patients versus 1.5% in 68 BPH patients. When a selected panel of six TAAs including p90 were used for immunoscreening, the cumulative positive reactions in prostate cancer sera reached 92.5%, significantly higher than in BPH and other control sera. Antibodies to p90 showed the highest frequency in prostate cancer (30.8%), followed by antibodies to p62 (22.6%).


CONCLUSIONS
A panel of six selected TAAs was shown to have high sensitivity and specificity as immunodiagnostic markers in prostate cancer.
Shi
Fu-Dong
FD
Department of Molecular and Experimental Medicine, W.M. Keck Autoimmune Disease Center, The Scripps Research Institute, La Jolla, California, USA.
Zhang
Jian-Ying
JY
Liu
Daorong
D
Rearden
Ann
A
Elliot
Max
M
Nachtsheim
Dan
D
Daniels
Tracy
T
Casiano
Carlos A
CA
Heeb
Mary Jo
MJ
Chan
Edward K L
EK
Tan
Eng M
EM
D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D016213:Cyclins / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D008565:Membrane Proteins; D010446:Peptide Fragments / Q000276:immunology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000276:immunology*; D016271:Proto-Oncogene Proteins c-myc / Q000276:immunology; D012333:RNA, Messenger; D016601:RNA-Binding Proteins / Q000276:immunology*; D011994:Recombinant Proteins; D012680:Sensitivity and Specificity; D016159:Tumor Suppressor Protein p53 / Q000276:immunology
D000951:Antigens, Neoplasm; D001323:Autoantibodies; D001324:Autoantigens; D014408:Biomarkers, Tumor; C500266:CIP2A protein, human; D016213:Cyclins; D047908:Intracellular Signaling Peptides and Proteins; C489427:MYC protein, human; D008565:Membrane Proteins; C118585:P62 protein, human; D010446:Peptide Fragments; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D016601:RNA-Binding Proteins; D011994:Recombinant Proteins; D016159:Tumor Suppressor Protein p53; D017430:Prostate-Specific Antigen